Medical Xpress August 22, 2024
The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also have heart failure, according to a new study led by UCL’s Professor John Deanfield.
The results follow previous research from the same international team finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such as heart attacks and strokes for people with obesity or who were overweight and had cardiovascular disease.
The new study, published in The Lancet, found similar cardiovascular benefits for a subgroup of study participants who were also judged to have heart failure (i.e. whose hearts did not pump blood...
Today's Sponsors
Today's Sponsor